Real-world outcomes with CDK4/6 inhibitors for HR+/HER2- metastatic breast cancer in patients aged 80 years or older

Patients aged ≥ 80 years with HR+/HER2- metastatic breast cancer are underrepresented in clinical trials, leaving clinicians with limited data to guide treatment decisions. A multicenter retrospective study in Italy investigated real-world outcomes with CDK4/6 inhibitors in this patient group. The study found that CDK4/6 inhibitor-based therapy is feasible in this group, with outcomes and tolerability comparable to those observed in younger patients.